Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens

Journal of Clinical Investigation

Volumn 122, Issue 8, 2012, Pages 2741-2748

  Holtzman, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ASTHMA; CHRONIC DISEASE; DENDRITIC CELL; EPITHELIUM CELL; HUMAN; INNATE IMMUNITY; LYMPHOID CELL; MACROPHAGE; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRAL RESPIRATORY TRACT INFECTION;

ADAPTIVE IMMUNITY; ALLERGENS; ANIMALS; ASTHMA; HUMANS; IMMUNITY, INNATE; MICE; MODELS, IMMUNOLOGICAL; RESPIRATORY MUCOSA; RESPIRATORY TRACT INFECTIONS; VIRUS DISEASES;

EID: 84864742968     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60325     Document Type: Review

References (140)

1. Mosmann TG, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173. (Pubitemid 19138011)
2. Robinson DS, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326(5):298-304.
3. Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol. 2010;72:495-516.
4. Horka H, et al. The tick salivary protein sialostatin L inhibits the Th9-derived production of the asthma- promoting cytokine IL-9 and is effective in the prevention of experimental asthma. J Immunol. 2012;188(6):2669-2676.
5. Oertli M, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest. 2012;122(3):1082-1096.
6. Poston RN, Chanez P, Lacoste JY, Litchfield T, Lee TH, Bousquet J. Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi. Am Rev Respir Dis. 1992;145(4 pt 1):918-921.
7. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon γ) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol. 1995;12(5):477-487.
8. Hollams EM, et al. Elucidation of asthma phenotypes in atopic teenagers through parallel immunophenotypic and clinical profiling. J Allergy Clin Immunol. 2009;124(3):463-470.
9. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003;111(4):661-675. (Pubitemid 36470230)
10. Morgan WJ, et al. Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence. Am J Respir Crit Care Med. 2005;172(10):1253-1258. (Pubitemid 43076563)
11. Kusel MM, et al. Early-life respiratory viral infections, atopic sensitization and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007;119(5):1105-1110. (Pubitemid 46654175)
12. Castro M, et al. Cytokine response after severe respiratory syncytial virus bronchiolitis in early life. J Allergy Clin Immunol. 2008;122(4):725-733.
13. Thomsen SF, et al. Exploring the association between severe respiratory syncytal virus infection and asthma: a registry-based twin study. Am J Respir Crit Care Med. 2009;179(12):1091-1097.
14. Sigurs N, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045-1052.
15. Koponen P, Helminen M, Paassilta T, Luukkaala T, Korppi M. Preschool asthma after bronchiolitis in infancy. Eur Respir J. 2012;39(1):76-80.
16. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and Type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003;168(6):633-639. (Pubitemid 37175965)
17. Copenhaver CC, et al. Cytokine response patterns, exposure to viruses, and respiratory infections in the first year of life. Am J Respir Crit Care Med. 2004;170(2):175-180. (Pubitemid 38925164)
18. Message SD, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105(36):13562-13567.
19. Olenec JP, et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J Allergy Clin Immunol. 2010;125(5):1001-1006.
20. Rakes GP, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med. 1999;159(3):785-790. (Pubitemid 29137774)
21. Jackson DJ, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med. 2012;185(3):281-285.
22. Papadopoulos NG, et al. Viruses and bacteria in acute asthma exacerbations-a GA2LEN-DARE systematic review. Allergy. 2011;66(4):458-468.
23. Mandelswajg A, Moulin F, Menager C, Rozenberg F, Lebon P, Gendrel D. Underestimation of influenza viral infection in childhood asthma exacerbations. J Pediatr. 2010;157(3):505-506.
24. Nguyen-Van-Tam JS, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax. 2010;65(7):645-651.
25. Kloepfer KM, et al. Increased H1N1 infection rate in children with asthma. Am J Respir Crit Care Med. 2012;185(12):1275-1279.
26. Stein RT, Martinez FD. Respiratory syncytial virus and asthma: still no final answer. Thorax. 2010;65(12):1033-1034.
27. Carroll KN, et al. Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. J Allergy Clin Immunol. 2012;129(5):1236-1242.
28. Subrata LS. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol. 2009;183(4):2793-2800.
29. Holt PG, et al. Towards improved prediction of risk for atopy and asthma amongs preschoolers: a prospective cohort study. J Allergy Clin Immunol. 2010;125(3):653-659.
30. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259-1260. (Pubitemid 19280051)
31. Holt PG, et al. Genetic 'risk' for atopy is associated with delayed postnatal maturation of T-cell competence. Clin Exp Allergy. 1992;22(12):1093-1099. (Pubitemid 23011171)
32. Ege MJ, et al. Exposure to environmental microorganisms and childhood asthma. N Eng J Med. 2011;364(8):701-709.
33. Holtzman MJ, Sampath D, Castro M, Look DC, Jayaraman S. The one-two of T helper cells: does interferon-γ knockout the Th2 hypothesis for asthma? Am J Respir Cell Mol Biol. 1996;14(4):316-318. (Pubitemid 126440496)
34. Holtzman MJ. Where are the gaps in asthma research? A counter-perspective. J Allergy Clin Immunol. 2003;111(2):244-247. (Pubitemid 36228540)
35. Holtzman MJ. Drug development for asthma. Am J Respir Cell Mol Biol. 2004;29(2):163-179.
36. Sumino K, et al. Antiviral IFN-γ responses of monocytes at birth predict respiratory tract illness in the first year of life. J Allergy Clin Immunol. 2012; 129(5):1267-1273.e1.
37. Miksch JS, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63(5):453-462. (Pubitemid 351698876)
38. Busse WW, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015.
39. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet. 2007;370(9596):1396-1398.
40. Corren J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ra antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181(8):788-796.
41. Corren J. Anti-interleukin-5 antibody therapy in asthma and allergies. Curr Opin Allergy Clin Immunol. 2011;11(6):565-570.
42. Corren J, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088-1098.
43. Holtzman MJ, et al. Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. Physiol Rev. 2002;82(1):19-46. (Pubitemid 34654214)
44. Zhang Y, Hinojosa ME, Holtzman MJ. Viral and host strategies to take advantage of the innate immune response. Am J Respir Cell Mol Biol. 2010;43(5):507-510.
45. Byers DE, et al. Defining the role of the key cytokines (TSLP, IL-25, and IL-33) controlling IL-13 production and chronic obstructive lung disease under experimental and clinical conditions. Am J Respir Crit Care Med. 2012;184:A1294.
46. Shornick LP, et al. Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection. J Immunol. 2008;180(5):3319-3328.
47. Holtzman MJ, Patel D, Kim H, You Y, Zhang Y. Hypersusceptibility to respiratory viruses as a shared mechanism for asthma, COPD, and CF. Am J Respir Cell Mol Biol. 2011;44(6):739-742.
48. Dupuis S, et al. Impaired response to interferona/ b and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33(3):388-391.
49. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL. A defective type I response to rhinovirus in atopic asthma. Thorax. 2002;57(4):328-332. (Pubitemid 34298930)
50. Bufe A, Gehlhar K, Grage-Griebenow E, Ernst M. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol. 2002;127(1):82-88. (Pubitemid 34224957)
51. Guerra S, Lohman I, Halonen M, Martinez F, Wright A. Reduced interferon gamma production and soluble CD14 levels in early life predict recurrent wheezing by 1 year of age. Am J Respir Crit Care Med. 2004;169(1):70-76. (Pubitemid 38233891)
52. Macaubas C, et al. Association between antenatal cytokine production and the development of atopy and asthma at age 6 years. Lancet. 2003;362(9391):1192- 1197. (Pubitemid 37255345)
53. Aberle JH, Aberle SW, Rebhandl W, Pracher E, Kundi M, Popow-Kraupp T. Decreased interferongamma response in respiratory syncytial virus compared to other respiratory viral infections in infants. Clin Exp Immunol. 2004;137(1):146-150. (Pubitemid 38869789)
54. Gelhar K, Bilitewski C, Reinitz-Rademacher K, Rohde G, Bufe A. Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy. 2006;36(3):331-337. (Pubitemid 43344714)
55. Gern J, et al. Bidirectional interactions between viral respiratory illnesses and cytokine responses in the first year of life. J Allergy Clin Immunol. 2006;117(1):72-78. (Pubitemid 43017142)
56. Ly NP, et al. Cord blood cytokines and acute lower respiratory illnesses in the first year of life. Pediatrics. 2007;119(1):e171-e178. (Pubitemid 46397822)
57. Walter MJ, Look DC, Tidwell RM, Roswit WT, Holtzman MJ. Targeted inhibition of interferon-g-dependent ICAM-1 expression using dominant-negative Stat1. J Biol Chem. 1997;272(45):28582-28589. (Pubitemid 27517811)
58. Look DC, et al. Direct suppression of Stat1 function during adenoviral infection. Immunity. 1998;9(6):871-880. (Pubitemid 29024466)
59. Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and type I interferon responsiveness. J Virol. 2005;79(14):9315-9319. (Pubitemid 40934843)
60. Wark PA, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937-947. (Pubitemid 40524463)
61. Contoli M, et al. Role of deficient type III interferon-l production in asthma exacerbations. Nat Med. 2006;12(9):1023-1026. (Pubitemid 44353382)
62. Cakebread JA, et al. Exogenous IFN-b has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol. 2011;127(5):1148-1154.
63. Harada M, et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol. 2007;36(4):491-496. (Pubitemid 46623008)
64. Torgerson DG, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. 2011;43(9):887-893.
65. Zheng S, et al. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity. 2003;18(5):619-630. (Pubitemid 36588579)
66. Schneider D, et al. Increased cytokine resonse of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(3):332-340.
67. Mallia P, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183(6):734-742.
68. Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Narjour NN, Gern JE. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 2010;3(1):69-80.
69. Lopez-Souza N, et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol. 2009;123(6):1384-1390.
70. DeMore JP, et al. Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. J Allergy Clin Immunol. 2009;124(2):245-252.
71. Sampath D, Castro M, Look DC, Holtzman MJ. Constitutive activation of an epithelial signal transducer and activator of transcription (Stat1) pathway in asthma. J Clin Invest. 1999;103(9):1353-1361. (Pubitemid 29218306)
72. Bullens DM, et al. Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy. 2008;38(9):1459-1467.
73. Fort MM, et al. IL-25 induces IL-4, IL-5, and IL-13 pathologies and Th2-associated pathologies in vivo. Immunity. 2001;15(6):985-995. (Pubitemid 34075378)
74. Schmitz J, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type-2 associated cytokines. Immunity. 2005;23(5):479-490. (Pubitemid 41587888)
75. Wang Y-H, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007;204(8):1837-1847. (Pubitemid 47236321)
76. Kato A, Favoreto S, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol. 2007;179(2):1080-1087.
77. Ying S, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181(4):2790-2798.
78. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin". PloS One. 2008;3(10):e3331.
79. Terashima A, et al. A novel subset of mouse NKT cells bearing IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med. 2008;205(12):2727-2733.
80. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7(5):e1000067.
81. Zhou B, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6(10):1047-1053. (Pubitemid 41486190)
82. Ballantyne SJ, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2007;120(6):1324-1331. (Pubitemid 350216590)
83. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med. 2009;179(9):772-781.
84. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386(1):181-185.
85. Fallon PG, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth explusion. J Exp Med. 2006;203(4):1105-1116.
86. Moro K, et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+ Sca-1+ lymphoid cells. Nature. 2009;463(7280):540-544.
87. Neill DR, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367-1370.
88. Saenz SA, et al. IL-25 elicits a multi-potent progenitor cell population that promotes Th2 cytokine responses. Nature. 2010;464(7293):1362-1366.
89. Barlow JL, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol. 2011;129(1):191-198.
90. Price AE, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A. 2011;107(25):11489-11494.
91. Chang Y, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631-638.
92. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol. 1988;26(2):153-162.
93. Bartlett NW, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199-204. (Pubitemid 351214556)
94. Wang Q, et al. MDA5 and TLR3 initiate proinflammatory signaling pathways leading to rhinovirus-induced airways inflammation and hyperresponsiveness. PLoS Pathog. 2011;7(5):e1002070.
95. Bochkov YA, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627-632.
96. Holt PG, Vines J, Bilyk N. Effect of influenza virus infection on allergic sensitization to inhaled antigen in mice. Int Arch Allergy Appl Immunol. 1988;86(1):121-123.
97. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. Respiratory syncytial virus infection Results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest. 1997;100(1):226-233. (Pubitemid 27311261)
98. Al-Garawi A, et al. Shifting of immune responsiveness to house dust mite by influenza A infection: genomic insights. J Immunol. 2012;188(2):832-843.
99. Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest. 2002;110(2):165-175. (Pubitemid 34787353)
100. Patel AC, et al. Genetic segregation of airway disease traits despite redundancy of chloride channel calcium-activated (CLCA) family members. Physiol Genomics. 2006;25(3):502-513. (Pubitemid 43764772)
101. Tyner JW, et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest. 2006;116(2):309-321. (Pubitemid 43228348)
102. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Wodland DL. Type I interferons regulate cytolytic activity of memory CD8+ T cells in the lung airway during respiratory virus challenge. Immunity. 2010;33(1):95-105.
103. Tyner JW, et al. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med. 2005;11(11):1180-1187. (Pubitemid 43093665)
104. Grayson MH, et al. Controls for lung dendritic cell maturation and migration during respiratory viral infection. J Immunol. 2007;179(3):1438-1448.
105. Kohlmeier JE, et al. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol. 2009;183(7):4378-4384.
106. Sandau MM, Kohlmeier JE, Woodland DL, Jameson SC. IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool. J Immunol. 2010;184(1):35-44.
107. Grayson MH, et al. Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. J Exp Med. 2007;204(11):2759-2769. (Pubitemid 350044797)
108. Cheung DS, et al. Cutting Edge: CD49d+ neutrophils induce FcεRI expression on lung dendritic cells in a mouse model of postviral asthma. J Immunol. 2010;185(9):4983-4987.
109. Kim EY, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic inflammatory lung disease. Nat Med. 2008;14(6):633-640. (Pubitemid 351809546)
110. Benoit LA, Holtzman MJ. New immune pathways from chronic post-viral lung disease. Ann NY Acad Sci. 2010;1183:195-210.
111. Vasudev M, et al. Expression of high-affinity IgE receptor on human peripheral blood dendritic cells in children. PloS One. 2012;7(2):e32556.
112. Agapov E, et al. Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir Cell Mol Biol. 2009;41(4):379-384.
113. Byers DE, et al. Development of 15-lipoxygenase-1 (15-LOX1) and 15-lipoxygenase-2 (15-LOX2) as markers to stratify epithelial versus macrophage activities in chronic obstructive lung diseases. Am J Respir Crit Care Med. 2012;184:A1427.
114. +natural killer T cells in bronchial asthma. N Engl J Med. 2006;354(11):1117-1129.
115. Vijayanand P, et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. New Engl J Med. 2007;356(14):1410-1422. (Pubitemid 46556326)
116. Reynolds C, et al. Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma. J Allergy Clin Immunol. 2009;124(4):860-862.
117. Matangkasombut P, et al. Natural killer T cells in the lungs of patients with asthma. J Allergy Clin Immunol. 2009;123(5):1181-1185.
118. Chupp GL, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357(20):2016-2027. (Pubitemid 350106709)
119. Smithgall MD, Comeau MR, Yoon BP, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019-1030.
120. Kurowska-Stolarska M, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009;183(10):6469-6477.
121. Oboki K, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A. 2010;107(43):18581-18586.
122. Byers DE, et al. A distinct population of non-B, non-T (NBNT) cells express high levels of IL-13 during acute and chronic airway disease after viral infection. Am J Respir Crit Care Med. 2009;179(2):A4293.
123. Thomas PG, Dash P, Aldridge JR, Ellebedy AH, Doherty PC, Kanneganti T. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity. 2009;30(4):566-575.
124. Ichinohe T, Lee HK, Ogura Y, Flavell RA, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009;206(1):79-87.
125. Allen IC, et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 2009;30(4):556-565.
126. Gitlin L, et al. Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo. PLoS Pathog. 2010;6(1):e1000734.
127. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004;10(12):1366-1373. (Pubitemid 40022719)
128. Le Goffic R, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2006;2(6):e53.
129. Gowen BB, et al. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J Immunol. 2006;177(9):6301-6307. (Pubitemid 44628848)
130. Hutchens M, et al. TLR3 increases disease morbidity and mortality from vaccinia infection. J Immunol. 2008;180(1):483-491.
131. Rudd BD, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol. 2006;176(3):1937-1942. (Pubitemid 43134339)
132. Lukacs NW, Smit JJ, Mukherjee S, Morris SB, Nunez G, Lindell DM. Respiratory virus-induced TLR7 activation controls IL-17 associated increased mucus via IL-23 regulation. J Immunol. 2010;185(4):2231-2239.
133. Sigurs N, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137-141. (Pubitemid 40105412)
134. DeVincenzo JP, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182(10):1305-1314.
135. Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol. 2007;120(6):1233-1244. (Pubitemid 350225687)
136. Borden EC, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975-990. (Pubitemid 350201788)
137. Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity. 2010;43(3):248-254.
138. Zhang Y, et al. Modification of the Stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment. J Biol Chem. 2005;280(40):34306-34315. (Pubitemid 41443156)
139. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PloS One. 2012;7(5):e36594.
140. Byers DE, Holtzman MJ. Alternatively activated macrophages as cause or effect in asthma. Am J Respir Cell Mol Biol. 2010;43(1):1-4.